News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
High peripheral T cell diversity associated with lower risk of toxicity to dual ICI Therapy – JITC
faculty.mdanderson.org
Jan 3, 2025, 15:57

High peripheral T cell diversity associated with lower risk of toxicity to dual ICI Therapy – JITC

Journal for ImmunoTherapy of Cancer shared a post on X:

“New JITC article: High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.”

High peripheral T cell diversity associated with lower risk of toxicity to dual ICI Therapy - JITC

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC

Authors: Mehmet Altan et al.

T cell diversity

cancer Journal for ImmunoTherapy of Cancer (JITC) Mehmet Altan NSCLC OncoDaily Oncology
Special Coverage
Blog
Jan 3, 2025, 15:57
High peripheral T cell diversity associated with lower risk of toxicity to dual ICI Therapy - JITC
Blog
Jan 3, 2025, 15:31
Gaia Griguolo: TOP1 Mutations are more frequent after treatment with ADCs
Blog
Jan 3, 2025, 15:18
Elvina Almuradova: January is Cervical Cancer Awareness Month
Blog
Jan 3, 2025, 15:10
Unveiling the BGICC 2025 Congress Program
Career
Jan 3, 2025, 13:36
Cancer and Blood Specialists of Arizona Welcome Ronak Rakesh Shah to Its Physician Team
Insight
Jan 3, 2025, 13:31
Mitochondrial DNA's Role in Leukemia Development Explored by St. Jude Scientists
Science
Jan 3, 2025, 13:22
Myeloma Paper of the Day, January 3rd, suggested by Robert Orlowski
Blog
Jan 3, 2025, 13:00
The current treatment process with CAR T cells - Penn Medicine
Science
Jan 3, 2025, 12:51
Targeting Molecular Pathways to Control ICI Toxicities
Insight
Jan 3, 2025, 12:45
Drew Moghanaki: ‘Some pembrolizumab’ is better than ‘No pembrolizumab’ in patients scheduled for preop chemo
Insight
Jan 3, 2025, 12:40
Senthil Kumar: First-Line Therapy in RCC, Expanding Choices in a New Era
Insight
Jan 3, 2025, 12:36
Akhil Santhosh: Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer